This article was originally published in The Gray Sheet
Executive SummaryGoing public via initial public offering of 2 mil. shares of common stock at $12 per share. The Webster, Texas-based epilepsy device manufacturer plans to use proceeds from the sale for R&D efforts, expansion of sales and marketing activities and manufacturing capabilities, working capital and general corporate purposes. Morgan Stanley and Kidder, Peabody are underwriting.
You may also be interested in...
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.